Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences [Press Release]
Business Wire | 3 days 22 hours 59 minutes ago
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Piper Jaffray 21st Annual Health Care Conference on Wednesday, December 2, 2009 at 2:00 p.m. EST and at the 2009 Deutsche Bank Biotech Boston Confab on Tuesday, December 15, 2009 at 9:00 a.m. EST.

Vertex Pharmaceuticals Reports Third Quarter 2009 Financial Results and Highlights Recent Business and Clinical Progress [Press Release]
Business Wire | 29 days 42 minutes ago
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reviewed recent business and clinical progress and reported consolidated financial results for the quarter ended September 30, 2009.

Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration [Press Release]
PRNewswire | 15 days 4 hours 16 minutes ago
BEND, Oregon, November 9 /PRNewswire/ -- Bend Research Inc., a company with more than 30 years of experience in applying innovative pharmaceutical technologies to help clients solve their most difficult scientific and technical problems, announced today that it has entered into a collaboration with Vertex Pharmaceuticals Incorporated, a global biotechnology company headquartered in Cambridge, MA.

Interim Results from Study 107 Highlight the Potential Role of Telaprevir-Based Regimens in HCV Patients Who Failed Prior Treatment [Press Release]
Business Wire | 27 days 9 hours 43 minutes ago
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that treatment with telaprevir-based regimens in Study 107 resulted in high sustained viral response (SVR) rates in treatment-failure patients infected with hepatitis C virus (HCV). Interim results from 94 patients in Study 107 showed that 90% of prior treatment relapsers (n=29) and 55% of prior treatment partial responders (n=29) achieved an SVR after treatment with 24-week or 48-week telaprevir-based regimens, and 57% of pri...

Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences [Press Release]
Business Wire | 24 days 23 hours 46 minutes ago
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Oppenheimer 20th Annual Healthcare Conference on Wednesday, November 4, 2009 at 2:10 p.m. EST and at the Credit Suisse 18th Annual Healthcare Conference on Thursday, November 12, 2009 at 7:30 a.m. MST (9:30 a.m. EST).

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2009 Financial Results Conference Call and Webcast [Press Release]
Business Wire | 41 days 28 minutes ago
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2009 financial results on Monday, October 26, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.

More than 80% of Hepatitis C Patients Treated in Study C208 Achieved an SVR with Telaprevir-Based Regimens [Press Release]
Business Wire | 23 days 23 hours 13 minutes ago
More than 80 percent of hepatitis C patients in each arm of the Phase 2 Study C208 achieved a sustained viral response (SVR) with a telaprevir-based regimen according to results of an intent-to-treat (ITT) analysis announced today by Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX). The data from Study C208 will be presented in an oral presidential plenary session at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which began yesterday in Boston....

Critical Alerts for Wells Fargo, Alcoa, Hess, Sears, and Vertex Pharmaceuticals Released by Seven Summits Research [Press Release]
PRNewswire | 111 days 7 hours 11 minutes ago
...for Wells Fargo, Alcoa, Hess, Sears, and Vertex Pharmaceuticals Released by Seven Summits Research PRNewswire...Corporation , Sears Holdings Corporation , and Vertex Pharmaceuticals Incorporated . In today's unsure markets these brief...

Reportlinker Adds Small Molecule Kinase Inhibitors Report [Press Release]
PRNewswire | 77 days 6 hours 11 minutes ago
...Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc., Pfizer, Inc...Company Limited, Millennium Pharmaceuticals Inc, S*Bio Pte Ltd., Sanofi-Aventis, Vertex Pharmaceuticals Incorporated, and Wyeth. Market data and...

Canaccord Adams hosts 29th Annual Global Growth Conference: August 11-13, 2009: Boston [Press Release]
PRNewswire | 110 days 42 minutes ago
- Investor conference features 240 small and mid-cap companies in six sectors - - 50+ next-generation companies will present at the Private Company Showcase - - Knowledge sessions will feature key topics in targeted coverage areas -

BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company [Press Release]
PRNewswire | 110 days 10 hours 41 minutes ago
SAN DIEGO, Aug. 6 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc.

Spherix Incorporated Selects LaVoie Group As Corporate Communications/Public Relations Agency [Press Release]
PRNewswire | 42 days 3 hours 13 minutes ago
Spherix Incorporated Selects LaVoie Group...selected by Spherix Incorporated to represent them...stakeholders." Spherix Incorporated is a developer of...sanofi-aventis, Vertex Pharmaceuticals, Rockwell Medical...